Noxopharm Limited (NOXOF PINK) stock market data APIs
$0.045
0(0%)
as of January 17, 2025
Noxopharm Limited Financial Data Overview
Price chart is built with
Anychart
Noxopharm Limited, a biotech company, engages in the discovering and developing treatments for cancer and inflammation, and mRNA vaccines in Australia. It develops Sofra, a platform that focuses on the development of immunomodulators for mRNA vaccines and mRNA therapeutics, as well as for the treatment of autoimmune diseases; and Chroma technology platform to develop CRO-67 dual-cell therapy drug for the treatment of pancreatic cancer and various molecules for the treatment of autoimmune disease and hyperinflammatory conditions. The company also develops orphan drug designations to treat less common disease; and IONIC program with Veyonda, which is combined with the Bristol Myers Squibb checkpoint inhibitor Opdivo for the treatment of various solid tumor types. Noxopharm Limited was incorporated in 2015 and is based in Glenhaven, Australia.
Prev. Close
0.045
Open
0.045
Volume
0
High
0.045
Low
0.045
52 wk Range
0.03-0.045
Market Cap
14 782 K
Shares Outstanding
292 M
Revenue
2 400 K
EPS
-0.0031
Beta
0.689
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Noxopharm Limited data using free add-ons & libraries
Get Noxopharm Limited Fundamental Data
Noxopharm Limited Fundamental data includes:
- Net Revenue: 2 400 K
- EBITDA: -4 599 915
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2021-06-30
- EPS/Forecast: 0
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Noxopharm Limited News
New
Is Noxopharm (ASX:NOX) In A Good Position To Deliver On Growth Plans?
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and mining exploration companies often lose money for years before finding success with...
Will Noxopharm (ASX:NOX) Spend Its Cash Wisely?
Just because a business does not make any money, does not mean that the stock will go down. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recur...
Noxopharm (ASX:NOX) shareholders have endured a 51% loss from investing in the stock three years ago
If you are building a properly diversified stock portfolio, the chances are some of your picks will perform badly. But the last three years have been particularly tough on longer term Noxopharm Limite...
FDA Grants Orphan Drug Designation to Noxopharm for Sarcoma Treatment
SYDNEY, March 29, 2022--(BUSINESS WIRE)--Australian biotech company Noxopharm (ASX:NOX) has announced the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to Veyonda®, it...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
